SCHEMBL651784

SCHEMBL651784

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccccc1)Cc1ccc2[nH]ccc2c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.46
TSHR P16473 2/20 0.38
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
SLC6A3 Q01959 3/20 0.36
KDM4E B2RXH2 2/20 0.36
ALDH1A1 P00352 2/20 0.36
HPGD P15428 2/20 0.36
HSD17B10 Q99714 1/20 0.36
KLKB1 P03952 1/20 0.36
GRM2 Q14416 1/20 0.35
BCHE P06276 2/20 0.35
NPC1 O15118 1/20 0.34
PDE4B Q07343 1/20 0.33
HSD11B1 P28845 1/20 0.33
CRHR1 P34998 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
NR1H3 Q13133 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL650365 0.94 C5AR1 (0.45) C5AR1TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL649674 0.90 C5AR1 (0.40) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL648572 0.89 C5AR1 (0.63) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL651094 0.86 TSHR (0.50) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135922 0.85 C5AR1 (0.49) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5134746 0.84 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5073888 0.84 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD
SCHEMBL5135079 0.83 C5AR1 (0.38) C5AR1TSHRSLC6A2SLC6A4SLC6A3
SCHEMBL648994 0.83 CRHR1 (0.44) C5AR1TSHRBCHECRHR1
SCHEMBL5134962 0.83 C5AR1 (0.48) C5AR1TSHRKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed